Cargando…

Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision

BACKGROUND/AIMS: To evaluate baseline low-luminance visual acuity (LLVA) as a predictor of visual acuity improvement in patients with neovascular (wet) age-related macular degeneration (wAMD) receiving antivascular endothelial growth factor A (anti-VEGF) therapy. METHODS: In the HARBOR trial, 1084 t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frenkel, Ronald E P, Shapiro, Howard, Stoilov, Ivaylo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975848/ https://www.ncbi.nlm.nih.gov/pubmed/26541435 http://dx.doi.org/10.1136/bjophthalmol-2015-307575

Ejemplares similares

Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy
por: Zarbin, Marco A, et al.
Publicado: (2022)

Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report
por: Terheyden, Jan Henrik, et al.
Publicado: (2023)

Direct Treatment Costs of Neovascular Age-related Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditure
por: Yıldırım, Şeyda, et al.
Publicado: (2018)

Vision protection therapy for prevention of neovascular age-related macular degeneration
por: Luttrull, Jeffrey K., et al.
Publicado: (2023)

Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR
por: Freund, K. Bailey, et al.
Publicado: (2022)

Functional Outcomes of the Low Vision Depression Prevention Trial in Age-Related Macular Degeneration
por: Deemer, Ashley D., et al.
Publicado: (2017)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Lateral gain is impaired in macular degeneration and can be targeted to restore vision in mice
por: Rizzi, M., et al.
Publicado: (2022)

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Relationship Between Rod-Mediated Sensitivity, Low-Luminance Visual Acuity, and Night Vision Questionnaire in Age-Related Macular Degeneration
por: McGuinness, Myra B., et al.
Publicado: (2020)

The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration
por: Daldal, Hatice
Publicado: (2022)

Low-vision intervention in individuals with age-related macular degeneration
por: Gopalakrishnan, Sarika, et al.
Publicado: (2020)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Development of the Vision Impairment in Low Luminance Questionnaire
por: Pondorfer, Susanne G., et al.
Publicado: (2021)

Rare CIDEC coding variants enriched in age-related macular degeneration patients with small low-luminance deficit cause lipid droplet and fat storage defects
por: Kim, Sehyun, et al.
Publicado: (2023)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Efficacy of low-vision devices in elderly population with age-related macular degeneration
por: Singh, Kirti, et al.
Publicado: (2023)

Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis
por: Sadda, SriniVas, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial
por: Bittner, Ava K, et al.
Publicado: (2014)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Detection of Nonexudative Macular Neovascularization on Structural OCT Images Using Vision Transformers
por: Kihara, Yuka, et al.
Publicado: (2022)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Intraocular vision-improving devices in age-related macular degeneration
por: Grzybowski, Andrzej, et al.
Publicado: (2020)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida, David R P, et al.
Publicado: (2021)

Choroidal Neovascularization and Haller Vessel Morphology Associated with Vision and Treatment Number after 1 Year in Age-related Macular Degeneration
por: Kim, Seungmin, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
por: Miyata, Manabu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aori82ec3ai1s80uvnlgr132dl